Clinical Trials Browser

Phase 2 × INDUSTRY × Sezary Syndrome × Clear all

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT03902184 2024-11-08

TELLOMAK

Phase 2 Active not recruiting

170 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT02953301 2024-08-30

RESMAIN

Phase 2 Completed

201 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00071071 2023-05-18

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Phase 2 Completed

25 enrolled

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00071084 2023-04-28

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Phase 2 Completed

22 enrolled

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00425555 2021-08-20

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Phase 2 Completed

139 enrolled 21 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00490776 2021-08-18

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

Phase 2 Terminated

9 enrolled 6 charts

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02542124 2018-11-16

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Phase 2 Unknown

10 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00091559 2017-04-05

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

Phase 2 Completed

74 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00611208 2016-11-29

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

Phase 2 Completed

32 enrolled

DermatologicLymphoidOther hematologic neoplasm

Mycosis Fungoides, Sezary Syndrome, Leukemia, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT00431912 2015-07-08

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

Phase 2 Completed

25 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Clinical Trials

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

TELLOMAK

RESMAIN

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma